CClinicalTrials.gg
WithdrawnNCT03508167DelfosUpdated Jul 8, 2019

Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain.

A Phase 3 interventional study of Thermal Band and Dorilax® in Low Back Pain, sponsored by Ache Laboratorios Farmaceuticos S.A.. Withdrawn. Open to participants aged 18 Years to 54 Years. Per ClinicalTrials.gov, last updated 2019-07-08.

Sponsored by Ache Laboratorios Farmaceuticos S.A. · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Study design will be reformulated
Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 54 Years
Sex
All
01

Study summary

National clinical trial, phase III, monocentric, randomized, double-blind, controlled, parallel, study of superiority, in which two hundred and thirty four (234) participants of both sexes, aged equal or more than 18 years and equal or less than 54 years, will be randomly allocated in one of two treatment groups. The first group will use Dorilax® plus thermal band and the second group will use thermal band plus placebo. The results will show the efficacy and security of Dorilax® and compare the efficiency of Dorilax® and thermal band.

02

Conditions studied

  • Low Back Pain
03

In context

Back Pain

2,373 studies on the registry are indexed under Back Pain; 284 are open to participants now.

Browse Back Pain studies →

Lead sponsor

Ache Laboratorios Farmaceuticos S.A. is the lead sponsor of 34 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 54 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Participants of both sexes aged ≥ (greater than or equal) to 18 years and ≤ (less than or equal) to 54 years;
  2. Ability to understand and consent their participation in this clinical study, expressed by signing the Informed Consent Form (ICF);
  3. Patient with acute low back pain who responds to the pain period less than or equal to 3 days;
  4. Low back pain in intensity Moderate to severe which corresponds to the severity score at least to 2 scores, evaluated by a 6 scores categoric scale;
  5. No traumatic low back pain (with no traumatic lesion for at least 7 days before randomization)
  6. Low back pain not caused or related to any clinically significant systemic disease, based on investigator evaluation.

Exclusion criteria

Exclusion Criteria:

  1. Any finding of clinical observation (clinical / physical assessment) that is interpreted by the investigating physician as a risk to the participation of the research participant in the clinical study;
  2. Any laboratorial finding that the Investigator consider a risk to subject of the study;
  3. Any finding of a previous imaging examination that the investigator considers to be a risk for clinical study participation;
  4. Known hypersensitivity to the components of the medicines used during the study;
  5. Women in pregnancy or nursing period;
  6. Women who do not agree to use acceptable contraceptive methods (oral contraceptive, intravenous contraceptive, intrauterine device (IUD), hormonal implant, barrier methods, hormonal transdermal patch and tubal ligation); except for those surgically sterile (bilateral oophorectomy or hysterectomy), menopause for at least one year, and participants who report not engaging in sexual practices or non-reproductive practices;
  7. Male participants who did not agree to use acceptable methods of contraception;
  8. Subjects that has participated in clinical trial protocols in the last twelve (12) months (National Board of Health- Resolution 251 of 07 August 1997, Part III, sub-item J), unless the investigator considers that there may be a direct benefit to it;
  9. Subjects who have a relationship of kinship to second degree or any bond with the sponsor or research center employees;
  10. Any serious medical illness, at the discretion of the investigator. For example, sciatica that extends below the knee [associated with numbness, tingling, and acute and irradiated pain]) or other neurological deficits (eg, altered straight leg elevation test, abolished or diminished patellar reflex, function of the intestine and / or bladder); Orthopedic surgery history;Fibromyalgia; Diabetes mellitus; peripheral vascular disease; Osteoporosis; Gastrointestinal ulcers; Bleeding or perforation of the gastrointestinal tract; kidney disease; pulmonary edema; Cardiomyopathy; Liver disease; intrinsic defects of coagulation; Hemorrhagic diseases;
  11. Any skin lesions (eg rash, bruising, swelling, irritation, laceration, excoriation, ulceration) in the lower back.
  12. Use of β-adrenergic blocking agents, antidepressant drugs or supplements that have effects on the central nervous system or that used short- or long-acting analgesic drugs within 24 to 48 hours before randomization, respectively.
  13. History of alcohol and / or illicit drug abuse, involvement in active litigation, or worker's compensation claim involving lumbar spine deficiency, back pain for more than 28 consecutive days, or heat hypersensitivity or NSAIDs.
  14. Subjects with febrile condition (axillary temperature greater or equal to 37.8ºC)
  15. Subjects who have recently had a bacterial infection (last 90 days) that affect the vertebral column, pelvic or abdominal region; as well as participants with a history of bacterial infection that affected the spine in a chronic way;
  16. Subjects with unexplained weight loss (more than 10 kg in the last three months);
  17. Subjects who are performing some type of oral, physical or topical treatment for low back pain (eg acupuncture, local heat and yoga) and / or initiation of physiotherapy program in the last 2 months before the start of therapy. study;
  18. Diabetic subjects, controlled or not.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Thermal Band plus Dorilax®

    Device: Thermal Band · Drug: Dorilax®

  • Other
    Thermal Band plus Placebo

    Device: Thermal Band · Drug: Placebo

Interventions

  • DeviceThermal Band

    Thermal Band used 8 hours per day

  • DrugDorilax®

    2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations. Maximum dosage per day: 6 tablets.

  • DrugPlacebo

    2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations. Maximum dosage per day: 6 tablets.

06

What researchers measure

Primary outcomes

  1. Compare the efficacy and security of Dorilax® plus thermal banc and Placebo plus thermal band

    The relief of the pain will be evaluated using a 6 points scale. 0 = no relief; 1 = little relief; 2 = less than half of relief; 3 = more than half of relief; 4 = a lot of relief; 5 = complete relief; The first 2 hours will be evaluated at the center and the other 6 hours the subject will need to provide a diary completed hourly with the pain evaluation.

    Time frame: 8 hours

Secondary outcomes

  1. Evaluation of participant satisfaction with treatment

    Satisfaction of the research participant with the treatment, evaluated in the final visit (VF) by means of the visual analog scale of 100 points (EVA of 100mm, being 0mm = totally unsatisfied and 100mm = totally satisfied).

    Time frame: 72 (+24) hours

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03508167
Lead sponsor
Ache Laboratorios Farmaceuticos S.A.
Responsible party
Sponsor
First posted
Apr 25, 2018
Start date
Jan 2020 (estimated)
Primary completion
Oct 2020 (estimated)
Completion
Nov 2020 (estimated)
Last update
Jul 8, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion